JP2020186248A5 - - Google Patents

Download PDF

Info

Publication number
JP2020186248A5
JP2020186248A5 JP2020128994A JP2020128994A JP2020186248A5 JP 2020186248 A5 JP2020186248 A5 JP 2020186248A5 JP 2020128994 A JP2020128994 A JP 2020128994A JP 2020128994 A JP2020128994 A JP 2020128994A JP 2020186248 A5 JP2020186248 A5 JP 2020186248A5
Authority
JP
Japan
Prior art keywords
antibody
seq
polypeptide
bispecific antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020128994A
Other languages
English (en)
Japanese (ja)
Other versions
JP7003347B2 (ja
JP2020186248A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020186248A publication Critical patent/JP2020186248A/ja
Publication of JP2020186248A5 publication Critical patent/JP2020186248A5/ja
Priority to JP2021150755A priority Critical patent/JP7241827B2/ja
Application granted granted Critical
Publication of JP7003347B2 publication Critical patent/JP7003347B2/ja
Priority to JP2023035060A priority patent/JP7635285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020128994A 2015-01-02 2020-07-30 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 Active JP7003347B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021150755A JP7241827B2 (ja) 2015-01-02 2021-09-16 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2023035060A JP7635285B2 (ja) 2015-01-02 2023-03-07 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562099236P 2015-01-02 2015-01-02
US62/099,236 2015-01-02
US201562200363P 2015-08-03 2015-08-03
US62/200,363 2015-08-03
US201562261609P 2015-12-01 2015-12-01
US62/261,609 2015-12-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017534345A Division JP6744313B2 (ja) 2015-01-02 2015-12-31 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021150755A Division JP7241827B2 (ja) 2015-01-02 2021-09-16 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Publications (3)

Publication Number Publication Date
JP2020186248A JP2020186248A (ja) 2020-11-19
JP2020186248A5 true JP2020186248A5 (https=) 2021-04-30
JP7003347B2 JP7003347B2 (ja) 2022-02-04

Family

ID=56285069

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017534345A Active JP6744313B2 (ja) 2015-01-02 2015-12-31 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2020128994A Active JP7003347B2 (ja) 2015-01-02 2020-07-30 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2021150755A Active JP7241827B2 (ja) 2015-01-02 2021-09-16 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2023035060A Active JP7635285B2 (ja) 2015-01-02 2023-03-07 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017534345A Active JP6744313B2 (ja) 2015-01-02 2015-12-31 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021150755A Active JP7241827B2 (ja) 2015-01-02 2021-09-16 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2023035060A Active JP7635285B2 (ja) 2015-01-02 2023-03-07 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Country Status (13)

Country Link
US (2) US11390687B2 (https=)
EP (2) EP3240570B1 (https=)
JP (4) JP6744313B2 (https=)
KR (1) KR102670705B1 (https=)
CN (2) CN107405399B (https=)
AU (2) AU2015373910B2 (https=)
CA (1) CA2972800A1 (https=)
CO (1) CO2017007123A2 (https=)
EA (1) EA201791527A1 (https=)
IL (2) IL253180B2 (https=)
MX (2) MX2017008541A (https=)
NZ (1) NZ771568A (https=)
WO (1) WO2016109774A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107405399B (zh) 2015-01-02 2022-02-08 武田药品工业株式会社 针对血浆激肽释放酶和因子xii的双特异性抗体
AU2016297018B9 (en) * 2015-07-21 2022-12-01 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor XIIa
EA201990730A1 (ru) * 2016-09-16 2019-08-30 Дайэкс Корп. Рнк-биомаркеры для наследственного ангионевротического отека
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110944661A (zh) 2017-02-20 2020-03-31 蜻蜓疗法股份有限公司 结合her2、nkg2d和cd16的蛋白质
EP3668893A4 (en) * 2017-08-16 2021-08-04 Dragonfly Therapeutics, Inc. PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1
MX2020003888A (es) * 2017-10-18 2020-11-06 Regenxbio Inc Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
CN119291194A (zh) * 2018-01-12 2025-01-10 建新公司 用于定量多肽的方法
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
JP7412001B2 (ja) * 2018-06-08 2024-01-12 株式会社モダリス 改変されたＣａｓ９タンパク質及びその用途
JP2021530989A (ja) * 2018-07-11 2021-11-18 モメンタ ファーマシューティカルズ インコーポレイテッド ＰＤ−Ｌ１を標的とした改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
JP2021534096A (ja) * 2018-08-08 2021-12-09 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
JP2022512688A (ja) * 2018-10-24 2022-02-07 シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用
BR112022001368A2 (pt) 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
US20230390418A1 (en) * 2020-10-29 2023-12-07 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
CN114790245A (zh) * 2021-01-25 2022-07-26 成都康弘生物科技有限公司 一种抗体及其用途
CN114790246A (zh) * 2021-01-25 2022-07-26 成都康弘生物科技有限公司 一种抗体及其用途
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
MX2023012489A (es) * 2021-04-22 2023-11-22 Guangdong Fapon Biopharma Inc Polipeptido de fusion biespecifico multifuncional.
WO2024238407A2 (en) * 2023-05-12 2024-11-21 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
CA2082643A1 (en) 1990-05-10 1991-11-11 Jan H. Nuijens Inhibitors of factor xii activation and applications thereof
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
GB9609262D0 (en) 1996-05-02 1996-07-03 Isis Innovation Peptide library and method
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
CN101260156A (zh) * 2002-06-28 2008-09-10 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
CA2591786C (en) 2004-12-23 2013-07-16 Bernhard Nieswandt Prevention of thrombus formation and/or stabilization
GB0500487D0 (en) 2005-01-11 2005-02-16 Axis Shield Diagnostics Ltd Forms of factor XIIa
US7932021B2 (en) 2005-07-28 2011-04-26 American Diagnostica, Inc. Lupus anticoagulant testing
GB0607515D0 (en) 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
TWI496582B (zh) * 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
PT2373691T (pt) 2008-12-18 2019-05-08 Univ Vanderbilt Anticorpos anti-fxi e métodos de utilização
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
KR102320178B1 (ko) * 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
IL230564B2 (en) 2011-07-22 2023-09-01 Csl Ltd Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
EP2548892A1 (en) * 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
JP5653860B2 (ja) 2011-07-28 2015-01-14 富士フイルム株式会社 管壁の硬度測定方法および装置
JP6271251B2 (ja) * 2011-10-05 2018-01-31 中外製薬株式会社 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
EP2847228B1 (en) 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2014019644A1 (en) * 2012-07-31 2014-02-06 Baxter International Inc. Selective measurement of active human protease coagulation factors
US9574013B2 (en) 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
US10690670B2 (en) 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
AU2014240045A1 (en) * 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
CA2916399C (en) * 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
CN107405399B (zh) 2015-01-02 2022-02-08 武田药品工业株式会社 针对血浆激肽释放酶和因子xii的双特异性抗体
AU2016297018B9 (en) * 2015-07-21 2022-12-01 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor XIIa
EP3263803B1 (en) 2016-06-30 2019-08-14 ABB Schweiz AG Substation

Similar Documents

Publication Publication Date Title
JP2020186248A5 (https=)
JP2018502572A5 (https=)
JP7209464B2 (ja) ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体
CN110831626B (zh) 单价抗备解素抗体及抗体片段
JP2020031650A (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
TWI585104B (zh) 基於vl和vhh可變區衍生物的高親和力抗聚集抗體
US11384141B2 (en) Serum albumin binding antibodies for tuneable half-life extension of biologics
CN111526887B (zh) 用于使血清中的蛋白质半衰期增加的组合物和方法
JP2021191789A (ja) 抗補体Ｂｂ因子抗体及びその使用
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
CN108610418A (zh) 抗补体C1s抗体和其用途
KR20220044748A (ko) 4가 대칭 이중 특이적 항체
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
JP7797203B2 (ja) 抗ｇａｌ９免疫阻害性結合分子
RS55775B2 (sr) Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
EP4421095A1 (en) Anti-mesothelin nanobodies and use thereof
CA3218571A1 (en) Methods of screening and expression of disulfide-bonded binding polypeptides
CN102257009A (zh) 具有针对dc-sign的结合特异性的配体
US20230227536A1 (en) Immunogenicity-reduced low-molecular antibody and method for producing same
US20230265187A1 (en) Anti-tigit antibody and methods of use thereof
JP2022537672A (ja) 抗ｂ７－ｈ３抗体およびその使用方法
Aoki Development of Mirror-Image VHHs with Less Immunogenicity
WO2023097363A1 (en) Improved binding proteins and uses thereof